<SEC-DOCUMENT>0000950123-21-007857.txt : 20210819
<SEC-HEADER>0000950123-21-007857.hdr.sgml : 20210819
<ACCEPTANCE-DATETIME>20210614171504
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-21-007857
CONFORMED SUBMISSION TYPE:	DRSLTR
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20210614

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cytek BioSciences, Inc.
		CENTRAL INDEX KEY:			0001831915
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				472547526
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRSLTR

	BUSINESS ADDRESS:	
		STREET 1:		46107 LANDING PARKWAY
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94538
		BUSINESS PHONE:		(877) 922-9835

	MAIL ADDRESS:	
		STREET 1:		46107 LANDING PARKWAY
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94538

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cytek BioSciences, Inc.
		DATE OF NAME CHANGE:	20201110
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRSLTR
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>DRSLTR</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g80783logo.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gordon Ho </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1
650 843 5190 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">gho@cooley.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June 14, 2021 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Securities and Exchange Commission </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Division of Corporation
Finance </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">100 F Street, N.E. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Washington, D.C. 20549 </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Attn:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Taylor Beech </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Dietrich King </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Eric Atallah </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Mary Mast </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Re:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Cytek Biosciences, Inc. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Draft Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Submitted April&nbsp;22, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>CIK No.&nbsp;0001831915 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and
Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On behalf of Cytek Biosciences, Inc. (the &#147;<B><I>Company</I></B>&#148;), we are responding to the comments (the
&#147;<B><I>Comments</I></B>&#148;) of the staff (the &#147;<B><I>Staff</I></B>&#148;) of the Securities and Exchange Commission (the &#147;<B><I>Commission</I></B>&#148;) contained in its letter, dated May&nbsp;18, 2021, relating to the above
referenced confidential draft Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (the &#147;<B><I>DRS</I></B>&#148;). In response to the Comments, the Company has revised the DRS and is confidentially submitting an amendment
to the DRS (the &#147;<B><I>Amended DRS</I></B>&#148;) with this response letter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For ease of reference, set forth below are the
Company&#146;s responses to the Comments. The numbering of the paragraphs below corresponds to the numbering of the Comments, which for your convenience we have incorporated into this response letter. Page references in the text of this response
letter correspond to the page numbers of the Amended DRS. Capitalized terms used in this letter but not otherwise defined herein have the meanings set forth in the Amended DRS. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Draft Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Cover page </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>We note your disclosure on page 59 that your executive officers, directors and current beneficial owners of
5% or more of your common stock will own a significant portion of your outstanding common stock, and, acting together, will be able to significantly influence all matters requiring stockholder approval, including the election and removal of
directors and any merger or other significant corporate transactions after completion of the offering. Please disclose here and in your prospectus summary the aggregate percent of the voting power these stockholders will control after the offering,
as you have done on page 59.</I> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Cooley LLP 3175 Hanover
Street Palo Alto, CA 94304-1130 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">t: (650) 843-5000 f: (650) 849-7400 cooley.com </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g80783logo.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June 14, 2021 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page Two </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>In response to the Staff&#146;s comment, the Company has revised the
disclosure in the prospectus summary on pages 6 and 7 of the Amended DRS. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Prospectus Summary, page 1 </U></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Please disclose the basis for the statement that you are a &#147;leading life sciences technology
company.&#148;</I> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>In response to the Staff&#146;s comment, the Company has revised the statement to
indicate that the Company is a &#147;leading cell analysis solutions company advancing the next generation of cell analysis tools.&#148; The Company<B> </B>respectfully submits that the basis for this statement is discussed throughout the Business
section. In particular, the Company believes its core instruments, the Aurora and Northern Lights systems, are the first full spectrum flow cytometers able to deliver high-resolution, high-content and high-sensitivity cell analysis by utilizing the
full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells (&#147;Full Spectrum Profiling&#148; or &#147;FSP&#148;). The Company&#146;s FSP technology enables achievement of higher levels of
multiplexing and sensitivity, as illustrated by our platform&#146;s ability to yield a <FONT STYLE="white-space:nowrap">40-color</FONT> Optimized Multicolor Immunofluorescence Panel (&#147;OMIP&#148;)&#151;the first OMIP publication to go beyond <FONT
STYLE="white-space:nowrap">28-color</FONT> fluorescence flow cytometry and exceeding OMIP panels published using mass cytometry&#151;and the more than 210 published peer-reviewed articles over three years across a wide range of applications
including oncology, infectious diseases, immunology, immunotherapy and immuno-oncology. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Please disclose in the &#147;Overview&#148; subsection that in the United States your products are currently
labeled and promoted, and are, and in the near-future will be, sold primarily to academic and research institutions and biopharmaceutical companies as research use only products, and are not currently designed, or intended to be used, for clinical
diagnostic tests. Please also disclose here that your Northern Lights system has been approved for clinical use only in Europe and China. </I> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response</B>: In response to the Staff&#146;s comment, the Company has revised the disclosure on page 3 of the Amended DRS. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Our Strategy, page 4 </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>In the fourth bullet, please clarify, if true, that your Northern Lights system has been approved for
clinical use in the European Union, as opposed to all of Europe.</I> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Cooley LLP 3175 Hanover
Street Palo Alto, CA 94304-1130 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">t: (650) 843-5000 f: (650) 849-7400 cooley.com </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g80783logo.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June 14, 2021 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page Three
</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>In response to the Staff&#146;s comment, the Company has revised the
disclosure on page 4 of the Amended DRS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations Liquidity and
Capital Resources, page 89</U> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Please revise to state specifically whether you anticipate needing to raise additional funds to carry out
your research and development investments, including your stated plans to seek approval or clearance from the FDA for clinical use of your Aurora and Northern Lights systems. </I> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>In response to the Staff&#146;s comment, the Company has revised the disclosure on page 98 of the Amended DRS. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Business Overview, page 99 </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>We note your disclosure that the total addressable market for flow cytometry technologies is nearly
$8</I><I></I><I>&nbsp;billion and that you believe your FSP platform has the potential to capture an increasingly greater share of the broader cell analysis market, which, according to industry sources, is expected to grow to roughly
$23</I><I></I><I>&nbsp;billion by 2024. Please disclose the industry sources upon which you are basing your calculations for each figure. In addition, please clarify whether these estimates include diagnostic markets, and if so, disclose that the
company</I><I>&#146;</I><I>s access to such market would depend in part upon FDA clearance or approval.</I> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response:
</B>In response to the Staff&#146;s comment, the Company has revised the disclosure on pages 109 and 110 of the Amended DRS. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Our Unique Optical
Design, page 107 </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Please enhance your graphic to ensure that all text is legible.</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>In response to the Staff&#146;s comment, the Company has included a higher resolution graphic on page 118 of the Amended DRS.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Reagents and Kits, page 120 </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>We note your disclosure that your TBNK reagents are currently being tested in clinical trials in China and
that you plan to seek Class</I><I></I><I>&nbsp;3 registration. To the extent material, please disclose where you stand in the clinical trial process, what steps you still need to complete, and when you anticipate seeking Class</I><I></I><I>&nbsp;3
registration.</I> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>In response to the Staff&#146;s comment, the Company has revised the disclosure on
page 131 of the Amended DRS. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Cooley LLP 3175 Hanover
Street Palo Alto, CA 94304-1130 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">t: (650) 843-5000 f: (650) 849-7400 cooley.com </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g80783logo.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June 14, 2021 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page Four </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Manufacturing and Supply, page 122 </U></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>We note your disclosure that key components in your products are supplied by sole or limited source
suppliers and that with respect to many suppliers, you do not have long term supply contracts. To the extent you do have supply contracts for these key components and you are substantially dependent on such agreements, please describe the material
terms of such agreements and file the agreements as exhibits. Alternatively, please explain the basis of your belief that such disclosure is not required. </I> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>The Company respectfully advises the Staff that the Company does not have long term supply contracts with any of its sole or
limited source suppliers of the key components in its products. The Company has revised the disclosure on page 133 of the Amended DRS to clarify the foregoing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Intellectual Property, page 123 </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Please revise to clarify the jurisdictions in which you own and have patents pending outside the United
States. With respect to your material patents, please disclose the specific products, product groups and technologies to which such patents relate, the type of patent protection you have, and the applicable jurisdictions and clarify whether there
are any contested proceedings or third-party claims.</I> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>In response to the Staff&#146;s comment, the
Company has revised the disclosure on page 134 of the Amended DRS and respectfully advises the Staff that the Company is not a party to any material legal proceedings, as disclosed on pages 134 and 135 of the Amended DRS. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Key Agreements, Licenses and Collaborations, page 124 </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>For each of the Biotium and BD Agreements, please disclose the amount of the upfront payments and remove the
corresponding redactions from Exhibits 10.11 and 10.12. With respect to the Biotium Agreement, please disclose a range for the &#147;single digit percentage&#148; royalty rate. With respect to the BD Agreement, please disclose the amount of the
milestone payment that you have included in the contractual obligations and commitments table on page 91 and remove the corresponding redactions in Exhibit 10.12.</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>In response to the Staff&#146;s comment, the Company has refiled Exhibits 10.11 and 10.12 and revised the disclosure on pages
135 and 136 of the Amended DRS. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Executive Compensation </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Summary Compensation Table, page 142 </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Please revise to include a more detailed discussion of the material terms of the <FONT
STYLE="white-space:nowrap">non-equity</FONT> incentive plan awards made to your named executive officers that includes a general description of the performance criteria applied in determining the amounts payable. Refer to Item 402(o)(4) of
Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT></I> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Cooley LLP 3175 Hanover
Street Palo Alto, CA 94304-1130 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">t: (650) 843-5000 f: (650) 849-7400 cooley.com </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g80783logo.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June&nbsp;14, 2021 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page Five
</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response</B>: In response to the Staff&#146;s comment, the Company has revised the
disclosure on page 154 of the Amended DRS. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Notes to consolidated financial statements</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Note 15 - Commitments and contingencies</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Legal
proceedings, page <FONT STYLE="white-space:nowrap">F-28</FONT></U> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>We note that you separated the settlement with Becton, Dickinson into two elements, litigation settlement
and future licensing rights. Please tell us the factors you considered in identifying the elements of the settlement. Disclose your allocation methodology and any significant assumptions used.</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response</B>: The Company respectfully advises the Staff of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company entered into the Settlement, License and Equity Issuance Agreement (the &#147;Settlement Agreement&#148;) with Becton, Dickinson
and Company (&#147;BD&#148;) in October 2020 , pursuant to which we settled claims for past damages and was granted from BD a license to certain of BD&#146;s intellectual property on a go forward basis. The Settlement Agreement specifies a royalty
to be paid by the Company to BD equal to a determined percentage of net sales of certain of the Company&#146;s products over a <FONT STYLE="white-space:nowrap">ten-year</FONT> period (the &#147;contractual royalty payments&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In identifying the Company&#146;s consideration of the separation and allocation of the components of the Settlement Agreement, the Company
considered a speech made by Eric West, then associate chief accountant in the SEC&#146;s Office of the Chief Accountant, at the 2007 AICPA Conference on Current SEC and PCAOB Developments, which states, in part: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Assume a company pays cash and conveys licenses to a plaintiff in order to settle a patent infringement and misappropriation of trade
secrets claim. In exchange for the payment and licenses given, the company receives a promise to drop the patent infringement lawsuit, a covenant not to sue with respect to the misappropriation of trade secrets claim, and a license to use the
patents subject to the litigation&#148;. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;West noted that the different elements of the arrangement should be identified, and that
this identification requires an understanding of the nature of each item. Mr.&nbsp;West further noted the following with respect to the amount of consideration to allocate to each element (<I><U>emphasis added</U></I>): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;While EITF <FONT STYLE="white-space:nowrap">00-21</FONT> was written for multiple element revenue arrangements, we believe that its
allocation guidance is also useful to determine how to allocate consideration paid in a multiple element legal settlement. <U>In this regard, we believe that it would be acceptable </U> </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Cooley LLP 3175 Hanover
Street Palo Alto, CA 94304-1130 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">t: (650) 843-5000 f: (650) 849-7400 cooley.com </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g80783logo.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June 14, 2021 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page Six </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>
<U>to value each element of the arrangement and allocate the consideration paid to each element using relative fair values</U>. <U>To the extent that one of the elements of the arrangement just
can&#146;t be valued, we believe that a residual approach may be a reasonable solution</U>. In fact, we have found that many companies are not able to reliably estimate the fair value of the litigation component of any settlement and have not
objected to judgments made when registrants have measured this component as a residual. In a few circumstances companies have directly measured the value of the litigation settlement component. <U>In the fact pattern that I just described, the
company may be able to calculate the value of the settlement by applying a royalty rate to the revenues derived from the products sold using the patented technology during the infringement period</U>. Admittedly, this approach requires judgment and
we are willing to consider reasonable judgment&#148;. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Applying the reasoning expressed in Mr.&nbsp;West&#146;s speech, the Company
determined the Settlement Agreement contains two elements: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The settlement of prior infringement claims (litigation settlement); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">License of intellectual property from BD for the utilization of defined
<FONT STYLE="white-space:nowrap">BD-owned</FONT> technology (future licensing rights). </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company allocated the
consideration transferred under the Settlement Agreement to both elements in a manner consistent with Mr.&nbsp;West&#146;s remarks and the allocation guidance within ASC 606. Although Mr.&nbsp;West referred to EITF
<FONT STYLE="white-space:nowrap">00-21</FONT> in his remarks, which was codified in ASC <FONT STYLE="white-space:nowrap">605-25,</FONT> we believe the allocation principles are similar to the guidance in ASC 606. The Company could not readily
determine the fair value of the litigation settlement of prior infringement claims between the Company and BD. Therefore, the Company applied the residual method and allocated the difference between the total present value consideration payable
under the Settlement Agreement and the estimated fair value of the future licensing rights to the litigation settlement element. Based in part on a valuation report from an independent third-party valuation specialist, the Company determined the
estimated fair value of the future licensing rights based on the relief from royalty method. The significant assumptions used were the market royalty rate estimated as a royalty rate that a market participant would pay to license the BD intellectual
property, forecasted sales subject to the market royalty rate, and the discount rate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>In response to the Staff&#146;s
comment, the Company has revised the disclosure on pages F-28 and F-29 of the Amended DRS. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>General </U></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Please supplementally provide us with copies of all written communications, as defined in Rule 405 under the
Securities Act, that you, or anyone authorized to do so on your behalf, present to potential investors in reliance on Section 5(d) of the Securities Act, whether or not they retain copies of the communications. Please contact the staff member
associated with the review of this filing to discuss how to submit the materials, if any, to us for our review.</I> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Cooley LLP 3175 Hanover
Street Palo Alto, CA 94304-1130 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">t: (650) 843-5000 f: (650) 849-7400 cooley.com </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g80783logo.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June&nbsp;14, 2021 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page
Seven </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response:</B> The Company is providing to the Staff, on a supplemental basis, copies of
the written communications, as defined in Rule 405 under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), that have been used in meetings with potential investors in reliance on Section&nbsp;5(d) of the Securities Act. These
materials were only made available for viewing by potential investors during the Company&#146;s presentations, and no copies were retained by any potential investor. Pursuant to Rule 418 under the Securities Act, the copies supplementally provided
shall not be deemed to be filed with, or a part of, or included in, the Registration Statement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">To the extent the Company conducts
additional meetings, it expects to use the same or similar materials, and the Company undertakes to provide the Staff with copies of any additional written communications that are presented to potential investors in the future by it or anyone
authorized to do so on its behalf in reliance on Section&nbsp;5(d) of the Securities Act, whether or not such potential investors retain copies of such communications. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Cooley LLP 3175 Hanover
Street Palo Alto, CA 94304-1130 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">t: (650) 843-5000 f: (650) 849-7400 cooley.com </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g80783logo.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June&nbsp;14, 2021 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page
Eight </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please contact me at (650) <FONT STYLE="white-space:nowrap">843-5190,</FONT> John McKenna at (650) <FONT
STYLE="white-space:nowrap">843-5059</FONT> or Ryan James at (650) <FONT STYLE="white-space:nowrap">843-5846</FONT> with any questions or further comments regarding the Company&#146;s response to the Staff&#146;s comments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sincerely, </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Gordon Ho</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Gordon Ho</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Cooley LLP</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">cc:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Wenbin Jiang, Cytek Biosciences, Inc. </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Valerie Barnett, Cytek Biosciences, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">John McKenna, Cooley LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Ryan
James, Cooley LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Ilir Mujalovic, Shearman&nbsp;&amp; Sterling LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Enclosures </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Cooley LLP 3175 Hanover
Street Palo Alto, CA 94304-1130 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">t: (650) 843-5000 f: (650) 849-7400 cooley.com </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g80783logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g80783logo.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1  (! @0$ P0'!00$  $"=P ! @,1
M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_  !$( "P A0,!$0 "$0$#$0'_V@ ,
M P$  A$#$0 _ /W ^(OQ+\&_"GPY/XH\:ZO%I6G1/Y%M$!YNH:G>E&>/3]*L
M5/F7MXRHS;$PJ(CR2M'%&[KS8O&8?!476Q$^2"T2^U)](Q6[?X):MI)L^EX5
MX1S_ (TS6GDW#V EC,7)<\Y?!1P])-*5?$U7[E&E%M+FEK*3C3IQG4E&$OSA
M\2_\% _'6N:F=-^%OPZTV&-IF6T.NIJ?B/6KV!"2LBZ9HEQ9QV4S#;NC$M^%
M&X"1B0R_)UN*,3.?)@\+&*OIS\U2;73W8.*3\O>MWZG]7Y1]&#AO+<&L7QGQ
M77E*,$ZBP;P^ PE&;W3Q&,A7E5A'7EDX89R=FX))Q<&B_M\?%3PWJ<=K\3?A
MMI$EF\B*T6GV>N>$]8AC67;=21KK%S?PWC1H1MA\JV^9=KS+OW)-/B;&T9J.
M+PL''JHJ=.?G\3DG;M9>IIC_ *,W!>;8.=7@_B[$QKPBVI5JN#S+"RDXWI1;
MPM/#5**DT^:ISUK1?-&D^7EE^F?@+QII/Q#\'>'_ !KH4=Y#I7B/3X]0LX-0
MBC@O;=6=XI(+J*&:6-9XIHI(V\N61"4RCLI!/V&%Q%/%X>EB*2:A55TI*S71
MII-JZ::T;79G\A\2Y!C>%L]S3A[,94IXW*:\J%65&4IT9M)2C.G*482<)QE&
M4>>$)I.THQDFEUU;GAA0 4 % !0 4 ?C;\(/^3_=6_[*A\;_ /TV^/Z^"P/_
M "4T_P#L(Q?_ *36/[WXZ_Y1CP/_ &3W"/\ Z?R4_9*OO3^" H * "@ H *
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M9_ZMY9BX*KAZ*H^VQM:BTI1K3C.=.EA:52#YJ4INK4E%<TJ,(2A*7E6F?\%
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(ZMON.H$?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
